Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro

Latest news

  • Merck says it has plenty in the pipe beyond Keytruda Merck says it has plenty in the pipe beyond Keytruda

    There’s certainly no sign of Keytruda slowing anytime soon, with new indications still rolling in, most recently for first-line head and neck cancer and second-line small cell lung ... largely thanks to its dominance in non-small cell lung cancer (NSCLC

  • EMD Serono allies with ‘free sequencing’ firm Nebula EMD Serono allies with ‘free sequencing’ firm Nebula

    In a blog post, Nebula notes that it is currently looking for lung cancer volunteers who are happy to share their data in return for a free high-coverage germline and ... Lung cancer is of particular interest to EMD/Merck as it builds a portfolio and

  • Keytruda begins pursuit of rivals in small cell lung cancer Keytruda begins pursuit of rivals in small cell lung cancer

    Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Keytruda can now be used as a monotherapy for small-cell lung cancer patients (SCLC) who have progressed

  • Hansoh Pharma shares head skyward after HKEX debut Hansoh Pharma shares head skyward after HKEX debut

    Since its inception it has become a major producer of generic cancer and central nervous system drugs for China’s domestic market, and has also brought two Category 1.1 innovative ... and has been filed for EGFR-positive non-small cell lung cancer

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    In the last few months alone, the company has claimed approvals for now fewer than four new targeted cancer drugs. ... That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna

More from news
Approximately 99 fully matching, plus 729 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Back in 2016, Chinese scientists led by oncologist Lu You at Sichuan University in Chengdu, injected CRISPR-modified cells into a patient with a form of lung cancer at the West ... hope was that - without the brake of PD-1 – the edited cells would

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year. ... Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of

  • Is China ready for a pharmaceutical gold rush?

    With most lung cancer patients already at an advanced stage when diagnosed, prolonging survival is an important goal. ... According to Chinese Government figures, there are about 781, 000 new lung cancer diagnoses in the country every year.

More from intelligence
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Quick links

Infographics

Multimedia